SecBot SecBot
SECBOTREPLAY Home › Report › SANA

SANA · Sana Biotechnology announced a strategic collaboration with Mayo Clinic…

Sana Biotechnology, Inc · PRESS-RELEASE filed Apr 13, 2026 at 16:05 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Apr 13, 2026 at 16:05 ET

Sana Biotechnology announced a strategic collaboration with Mayo Clinic to accelerate the development and clinical delivery of SC451, its investigational hypoimmune-modified pancreatic islet cell therapy for type 1 diabetes. As part of the partnership, Mayo Clinic is making an equity investment in Sana, with an option for additional investment.

  • Sana and Mayo Clinic are collaborating to advance SC451, a stem-cell derived islet cell therapy for type 1 diabetes.
  • Collaboration focuses on optimizing clinical protocols, surgical techniques, and post-treatment care to support global scalability.
  • Mayo Clinic is making an equity investment in Sana, with an option for additional investment.
  • SC451 is designed to provide long-term glucose control without insulin or immunosuppression.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access